Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweetorial #1




Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.


This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.


Prevalence, Role & Genomic Testing in Patients with HER Family Receptors


Genomic studies have identified human epidermal growth factor receptor 2 (HER2) as the main oncogenic driving force behind some types of particularly aggressive metastatic cancers: breast cancer (BC), gastrointestinal cancers (particularly gastric/gastroesophageal junction [GC/GEJ], colorectal cancer [CRC]), and even non-small cell lung cancer (NSCLC). HER2 appears to work in tandem with epidermal growth factor receptor (EGFR) family members, including the recently discovered HER3, in aggressive tumors with a poorer prognosis frequently characterized by treatment resistance. Fortunately, newly approved HER2-targeted treatment options work through varying mechanisms of action that may be able to obviate treatment resistance observed in older HER2-targeted pharmacologic agents. New and emerging treatments that target HER2 and HER3 may soon change standard of care for some types of HER2-driven cancers and will provide more highly personalized therapeutic options for patients with these types of metastatic cancer. This program will provide education on the prevalence, role, & genomic testing of HER family receptors in breast, gastric, and lung cancers.


Michael Pishvaian, MD, PhD
Associate Professor
Department of Oncology
Director of GI, Developmental Therapeutics, and Clinical Research Programs
John Hopkins Kimmel Cancer Center
Baltimore, Maryland


Aatur D. Singhi, MD, PhD
Associate Professor of Pathology
University of Pittsburgh
Pittsburgh, Pennsylvania


Release date: December 7, 2021
Expiration date: December 7, 2022
Estimated time to complete activity: 30 minutes



This educational activity has been designed to meet the needs of medical oncologists, pathologists, radiation oncologists, surgical oncologists and advanced practice providers (APPs) involved in the management of patients with solid tumors.


Upon completion of this educational activity, participants should be able to:

  • DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer
  • ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types
  • EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer

There are no fees for participating and receiving CME credit for this activity. During the period of December, 7, 2021 through December 7, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Tumor Board Tuesday. Integrity Continuing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with commercial interests related to the content of these CME activities:

Michael Pishvaian, MD, PhD
Consultant/Advisory Committees: AstraZeneca, Foundation Medicine, Merck
Ownership Interest: Perthera, Inc.
Funding to Institution: Arcus, Merck, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer

Aatur D. Singhi, MD, PhD
Consultant: Foundation Medicine

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.



Continue to Pretest